62 - Duration of Response to Ozanimod After Treatment Withdrawal: Results From the Phase 3 True North Study

Wednesday, October 26, 2022

9:40 AM – 9:50 AM ET

Location: Hall C2

Presenting Author(s)

Bruce E. Sands, MD, MS, FACG

Chief, Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
New York, NY

PDF of Slides View Slides

Bruce E. Sands, MD, MS, FACG¹, Bincy Abraham, MD, MS, FACG², Brian Bressler, MD, MS³, Walter Reinisch, MD, PhD⁴, Anjali Jain, PhD⁵, Arteid Memaj, MBA⁵, Lucy Akukwe, PharmD, MS⁵, W. Jerry Liu, MS⁵, Mark Osterman, MD, PhD⁵, James B. Canavan, BA, MB, BCh, BAO⁵, Séverine Vermeire, MD, PhD⁶
¹Icahn School of Medicine at Mount Sinai, New York, NY; ²Houston Methodist Academic Institute, Houston, TX; ³University of British Columbia, Vancouver, BC, Canada; ⁴Medical University of Vienna, Vienna, Wien, Austria; ⁵Bristol Myers Squibb, Princeton, NJ; ⁶University Hospitals Leuven, Leuven, Brussels Hoofdstedelijk Gewest, Belgium

Introduction: The phase 3 True North (TN) randomized trial demonstrated efficacy and safety of ozanimod (OZA) in patients (pts) with moderately to severely active ulcerative colitis (UC). Temporary discontinuation of UC treatment can occur in clinical practice. Understanding the duration of response after treatment discontinuation can assist in clinical decision making. This analysis examined time to loss of OZA response in pts who discontinued OZA and switched to placebo (PBO) in the TN maintenance period (MP).

Methods: In TN, pts were randomized to once-daily oral OZA 0.92 mg or PBO or to open-label OZA during a 10-week induction period (IP). Pts with clinical response to OZA at Week 10 were rerandomized to OZA (OZA-OZA) or PBO (OZA-PBO) in the MP through Week 52. Disease relapse was defined as an increase in partial Mayo score (PMS) of ≥2 points vs Week 10 with absolute PMS ≥4, endoscopic subscore ≥2, and exclusion of other causes of increased disease activity unrelated to UC. A subanalysis compared outcomes in OZA-OZA and OZA-PBO pts who entered the MP after achieving clinical remission (CRM) or clinical response (CRS only, excluding pts in CRM) at Week 10.

Results: In the TN MP, 230 pts continued OZA (CRM, n=82; CRS only, n=148) and 227 pts switched to PBO (CRM, n=79; CRS only, n=148). Baseline characteristics were generally similar between groups. Pts in CRS only at Week 10 had a numerically higher proportion with severe disease and prior immunosuppressive medication use vs CRM pts (Table). Differences in disease relapse between groups became apparent after MP Week 8, after which a significantly higher proportion of OZA-OZA pts were without relapse vs OZA-PBO pts (Figure). MP Week 42 Kaplan-Meier (KM) estimates of no relapse were 86.1% and 62.6% for OZA-OZA and OZA-PBO pts, respectively. Additionally, pts in CRM at Week 10 had higher rates of nonrelapse during the MP vs those in CRS only at MP entry. KM estimates of non-relapse at MP Week 42 were 67.9% and 59.7% in OZA-PBO pts with CRM and CRS, respectively, and 90.9% and 83.4% in OZA-OZA pts with CRM and CRS, respectively.

Discussion: This analysis shows that OZA is effective at preventing disease relapse over 42 weeks of maintenance treatment in pts who achieve clinical response at Week 10. These data show that OZA maintains disease control even in the event of temporary discontinuation. However, extended discontinuation should be minimized in clinical practice.

Figure: Figure 1.

	Pts in CRM^a at IP Week 10		Pts in CRS^b only at IP Week 10
	OZA-PBO (n=79)	OZA-OZA (n=82)	OZA-PBO (n=148)	OZA-OZA (n=148)
Age, years, mean ± SD	45.0 ± 13.5	42.7 ± 13.9	42.0 ± 13.8	42.3 ± 13.4
Males, n (%)	45 (57.0)	41 (50.0)	77 (52.0)	76 (51.4)
Years since UC diagnosis, mean ± SD	7.3 ± 7.0	7.4 ± 7.2	7.2 ± 7.3	8.9 ± 7.4
Prior therapies, n (%) 5-ASA CS Immunomodulator Anti-TNF Non-anti-TNF biologic	75 (94.9) 51 (64.6) 24 (30.4) 13 (16.5) 3 (3.8)	81 (98.8) 54 (65.9) 26 (31.7) 15 (18.3) 9 (11.0)	146 (98.6) 117 (79.1) 61 (41.2) 52 (35.1) 30 (20.3)	146 (98.6) 109 (73.6) 63 (42.6) 61 (41.2) 33 (22.3)
Complete Mayo score^c >9, n (%)	12 (15.2)	19 (23.2)	51 (34.5)	76 (51.4)
Mayo endoscopic score = 3 (severe), n (%)	22 (27.8)	25 (30.5)	94 (63.5)	107 (72.3)
Fecal calprotectin, median IQR, mg/kg	1027.8 (295.0, 2689.3)	851.6 (251.4, 2694.6)	1085.2 (434.4, 2579.3)	1285.0 (486.5, 2673.4)
All data are reported at IP baseline. ^aCRM was defined as complete Mayo score of ≤2 with no individual subscore of >1 point. ^bCRS was defined as decrease from baseline of ≥3 points and at least 30% in the complete Mayo score and a decrease of ≥1 in RBS or an absolute RBS of ≤1. ^cThe sum of the rectal bleeding subscore, stool frequency subscore, Physician’s Global Assessment subscore, and endoscopy subscore. ASA, aminosalicylic acid; CRM, clinical remission; CRS, clinical response; CS, corticosteroid; IP, induction period; SD, standard deviation; TNF, tumor necrosis factor.

Table: Table. Baseline characteristics in pts in CRM vs pts in CRS only at Week 10

Disclosures:

Bruce Sands: Abivax – Consultant, Speaking. Amgen – Consultant. Arena Pharmaceuticals – Consultant. Artugen Therapeutics – Consultant. AstraZeneca – Consultant. Bacainn Therapeutics – Consultant. Boehringer-Ingelheim – Consultant. Boston Pharmaceuticals – Consultant. Bristol Myers Squibb – Consultant, speaking, research funding. Calibr – Consultant. Celltrion Healthcare – Consultant. ClostraBio – Consultant. Eli Lilly and Company – Consultant. Entera – Consultant. Evommune – Consultant. Galapagos – Consultant. Genentech – Consultant. Gilead Sciences – Consultant. GlaxoSmithKline – Consultant. Gossamer Bio – Consultant. InDex Pharmaceuticals – Consultant. Innovation Therapeutics – Consultant. Inotrem – Consultant. Ironwood Pharmaceuticals – Consultant. Janssen – Consultant, Grant/Research Support, speaking. Kaleido – Consultant. Kallyope – Consultant. Miro Bio – Consultant. Morphic Therapeutics – Consultant. MRM Health – Consultant. Pfizer – Consultant, speaking. Progenity – Consultant. Prometheus Biosciences – Consultant. Protagonist Therapeutics – Consultant. Q32 Bio – Consultant. Surrozen – Consultant. Takeda – Consultant, Speaking. Teva – Consultant. TLL Pharmaceutical – Consultant. USWM Enterprises – Consultant. VielaBio – Consultant.

Bincy Abraham: AbbVie – Consultant, Speakers Bureau. Bristol Myers Squibb – Consultant, Speakers Bureau. Eli Lilly – Consultant, Speakers Bureau. Janssen – Consultant, Speakers Bureau. Medtronic – Consultant. Pfizer – Consultant, Speakers Bureau. Takeda – Consultant, Grant/Research Support, Speakers Bureau.

Brian Bressler: Abbvie – Advisor or Review Panel Member, Grant/Research Support, Speakers Bureau. Allergan – Advisor or Review Panel Member. Alvine – Grant/Research Support. Amgen – Advisor or Review Panel Member, Grant/Research Support. Boehringer Ingelheim – Grant/Research Support. Bristol Myers Squibb – Advisor or Review Panel Member, Grant/Research Support. Celgene – Advisor or Review Panel Member, Grant/Research Support. Ferring – Advisor or Review Panel Member, Speakers Bureau. Genentech – Advisor or Review Panel Member, Grant/Research Support. GSK – Grant/Research Support. Janssen – Advisor or Review Panel Member, Grant/Research Support, Speakers Bureau. Merck – Advisor or Review Panel Member, Grant/Research Support, Speakers Bureau. Microbiome Insights – Advisor or Review Panel Member. Novartis – Advisor or Review Panel Member, Speakers Bureau. Pendopharm – Advisor or Review Panel Member. Pfizer – Advisor or Review Panel Member, Speakers Bureau. Protagonist – Advisor or Review Panel Member. Qu Biologic – Grant/Research Support, Stock Options. Robarts Clinical Trials – Advisor or Review Panel Member. Takeda – Advisor or Review Panel Member, Speakers Bureau.

Walter Reinisch: 4SC – Advisory Committee/Board Member, Consultant. Abbott Laboratories – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speakers Bureau. AbbVie – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speakers Bureau. Aesca – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speakers Bureau. Algernon – Consultant. AM Pharma – Advisory Committee/Board Member, Consultant. Amgen – Advisory Committee/Board Member, Consultant. AMT – Consultant. AOP Orphan – Consultant. Aptalis – Speakers Bureau. Arena Pharmaceuticals – Consultant. Astellas – Advisory Committee/Board Member, Consultant, Speakers Bureau. AstraZeneca – Advisory Committee/Board Member, Consultant. Avaxia – Advisory Committee/Board Member, Consultant. Bioclinica – Consultant. Biogen IDEC – Advisory Committee/Board Member, Consultant. Boehringer Ingelheim – Advisory Committee/Board Member, Consultant. Bristol Myers Squibb – Advisory Committee/Board Member, Consultant. Celgene – Advisory Committee/Board Member, Consultant. Cellerix – Advisory Committee/Board Member, Consultant. Celltrion – Advisory Committee/Board Member, Consultant, Speakers Bureau. Centocor – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speakers Bureau. ChemoCentryx – Advisory Committee/Board Member, Consultant. Covance – Consultant. Danone Austria – Advisory Committee/Board Member, Consultant, Speakers Bureau. DSM – Advisory Committee/Board Member, Consultant. Elan – Advisory Committee/Board Member, Consultant, Speakers Bureau. Eli Lilly – Consultant. Ernest & Young – Consultant. Falk Pharma GmbH – Consultant, Grant/Research Support, Speakers Bureau. Ferring – Advisory Committee/Board Member, Consultant, Speakers Bureau. Galapagos – Advisory Committee/Board Member, Consultant. Gatehouse Bio – Consultant. Genentech – Advisory Committee/Board Member, Consultant. Gilead – Consultant. Grünenthal – Advisory Committee/Board Member, Consultant. ICON – Consultant. Immundiagnostik – Grant/Research Support, Speaker. Index Pharma – Consultant. Inova – Advisory Committee/Board Member, Consultant. Intrinsic Imaging – Consultant. Janssen – Advisory Committee/Board Member, Consultant, Grant/Research Support. Johnson & Johnson – Advisory Committee/Board Member, Consultant. Kyowa Hakko Kirin Pharma – Advisory Committee/Board Member, Consultant. Lipid Therapeutics – Advisory Committee/Board Member, Consultant. LivaNova – Consultant. Mallinckrodt – Consultant. Medahead – Consultant. MedImmune – Advisory Committee/Board Member, Consultant. Millenium – Advisory Committee/Board Member, Consultant. Mitsubishi Tanabe Pharma Corporation – Advisory Committee/Board Member, Consultant, Speakers Bureau. MSD – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speakers Bureau. Nash Pharmaceuticals – Consultant. Nestle – Advisory Committee/Board Member, Consultant. Nippon Kayaku – Consultant. Novartis – Advisory Committee/Board Member, Consultant. Ocera – Advisory Committee/Board Member, Consultant. OMass – Consultant. Otsuka – Advisory Committee/Board Member, Consultant, Speakers Bureau. Parexel – Consultant. PDL – Advisory Committee/Board Member, Consultant, Speakers Bureau. Periconsulting – Consultant. Pfizer – Advisory Committee/Board Member, Consultant. Pharmacosmos – Advisory Committee/Board Member, Consultant, Speakers Bureau. Philip Morris Institute – Consultant. PLS Education – Speakers Bureau. Procter & Gamble – Advisory Committee/Board Member, Consultant. Prometheus – Advisory Committee/Board Member, Consultant. Protagonist – Consultant. Provention – Consultant. Quell Therapeutics – Consultant. Robarts Clinical Trial – Consultant. Roland Berger GmbH – Consultant. Sandoz – Advisory Committee/Board Member, Consultant, Grant/Research Support. Schering-Plough – Advisory Committee/Board Member, Consultant, Speakers Bureau. Second Genome – Advisory Committee/Board Member, Consultant. Seres Therapeutics – Consultant. Setpoint Medical – Advisory Committee/Board Member, Consultant. Shire – Speakers Bureau. Sigmoid – Consultant. Sublimity – Consultant. Takeda – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speakers Bureau. Therakos – Advisory Committee/Board Member, Consultant, Speakers Bureau. Theravance – Consultant. TiGenix – Advisory Committee/Board Member, Consultant. UCB – Advisory Committee/Board Member, Consultant. Vifor – Consultant, Speakers Bureau. Yakult – Speakers Bureau. Zealand – Advisory Committee/Board Member, Consultant. Zyngenia – Advisory Committee/Board Member, Consultant.

Anjali Jain: Bristol Myers Squibb – Employee, Stock-publicly held company(excluding mutual/index funds).

Arteid Memaj: Bristol Myers Squibb – Employee, Stock-publicly held company(excluding mutual/index funds).

Lucy Akukwe: Bristol Myers Squibb – Employee, Stock-publicly held company(excluding mutual/index funds).

W. Jerry Liu: Bristol Myers Squibb – Employee, Stock-publicly held company(excluding mutual/index funds).

Mark Osterman: Bristol Myers Squibb – Employee, Stock-publicly held company(excluding mutual/index funds).

James Canavan: Bristol Myers Squibb – Employee, Stock-publicly held company(excluding mutual/index funds).

Séverine Vermeire: AbbVie – Consultant, Grant/Research Support. Arena – Consultant. Celgene – Consultant. Eli Lilly – Consultant. Ferring – Consultant. Galapagos – Consultant. Genentech/Roche – Consultant. Gilead – Consultant. Hospira – Consultant. Janssen – Consultant. Johnson & Johnson – Grant/Research Support. MSD – Consultant. Mundipharma – Consultant. Pfizer – Consultant, Grant/Research Support. Progenity – Consultant. Second Genome – Consultant. Shire – Consultant. Takeda – Consultant, Grant/Research Support.